Subject-Reported Changes in Physical Activity During The A-LONG Study of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) for Severe Haemophilia A

被引：0
|
作者：
Klamroth, R. [1 ]
Quon, D. V. [2 ]
Kulkarni, R. [3 ]
Shapiro, A. D. [4 ]
Baker, R. I. [5 ]
Castaman, G. [6 ]
Innes, A. [7 ]
Allen, G. [7 ]
机构：
[1] Vivantes Klinikum Friedrichshain, Zentrum Gefaessmed Haemophiliezentrum, Berlin, Germany
[2] Orthopaed Haemophilia Treatment Ctr, Los Angeles, CA USA
[3] Michigan State Univ, E Lansing, MI 48824 USA
[4] Indiana Haemophilia & Thrombosis Ctr, Indianapolis, IN USA
[5] Murdoch Univ, Western Australia Ctr Thrombosis & Haemostasis, Perth, WA, Australia
[6] Careggi Univ Hosp, Ctr Bleeding Disorders, Florence, Italy
[7] Biogen Idec Inc, Cambridge, MA USA
来源：
HAEMOPHILIA | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP035
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] Subject-Reported Changes in Physical Activity During The B-LONG Study of Recombinant Factor IX FC Fusion Protein (RFIXFC) For Severe Haemophilia B
    Windyga, J.
    Ragni, M.
    Pasi, J.
    Shapiro, A. D.
    Ozelo, M.
    Innes, A.
    Mei, B.
    HAEMOPHILIA, 2015, 21 : 29 - 29
  • [2] Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A
    Shapiro, A. D.
    Mahlangu, J. N.
    Perry, D.
    Pasi, J.
    Quon, D. V.
    Chowdary, P.
    Tsao, E.
    Li, S.
    Innes, A.
    Pierce, G. F.
    Allen, G. A.
    HAEMOPHILIA, 2017, 23 (03) : 392 - 399
  • [3] Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG)
    Young, G.
    Mahlangu, J.
    Kulkarni, R.
    Nolan, B.
    Liesner, R.
    Pasi, J.
    Barnes, C.
    Neelakantan, S.
    Gambino, G.
    Cristiano, L. M.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2015, 21 : 32 - 32
  • [4] PERIOPERATIVE MANAGEMENT OF PATIENTS WITH SEVERE HAEMOPHILIA A WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)
    Bocchinfuso, S.
    O'Donovan, M.
    Singleton, E.
    Benson, J.
    Byrne, M.
    Ryan, K.
    O'Donnell, J. S.
    O'Connell, N. M.
    HAEMOPHILIA, 2021, 27 : 105 - 106
  • [5] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies
    Quon, Doris V.
    Klamroth, Robert
    Kulkarni, Roshni
    Shapiro, Amy D.
    Baker, Ross I.
    Castaman, Giancarlo
    Kerlin, Bryce A.
    Tsao, Elisa
    Alien, Geoffrey
    BLOOD, 2015, 126 (23)
  • [6] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies
    Klamroth, R.
    Quon, D. V.
    Kulkarni, R.
    Shapiro, A. D.
    Baker, R. I.
    Castaman, G.
    Kerlin, B. A.
    Tsao, E.
    Allen, G.
    HAEMOPHILIA, 2016, 22 : 20 - 20
  • [7] Long-lasting recombinant factor VIII Fc fusion (rFVIIIFc) for perioperative management of subjects with haemophilia A in the phase 3 A-LONG study
    Mahlangu, J.
    Powell, J.
    Josephson, N.
    Klamroth, R.
    Parra Lopez, R.
    Morfini, M.
    Oldenburg, J.
    Pasi, J.
    Perry, D.
    Ragni, M.
    Shapiro, A. D.
    Dunkley, S.
    Apte, S.
    Krassova, S.
    Greblikas, F.
    Innes, A.
    Nugent, K.
    Brennan, A.
    Luk, A.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 459 - 459
  • [8] Treatment of bleeding episodes in subjects with haemophilia A with long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in the Phase 3 A-LONG study
    Ragni, M.
    Josephson, N.
    Mahlangu, J.
    Pasi, J.
    Perry, D.
    Powell, J.
    Shapiro, A. D.
    Krassova, S.
    Greblikas, F.
    Nugent, K.
    Brennan, A.
    Luk, A.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 928 - 929
  • [9] Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies
    Quon, D. V.
    Klamroth, R.
    Kulkarni, R.
    Shapiro, A. D.
    Baker, R. I.
    Castaman, G.
    Kerlin, B. A.
    Tsao, E.
    Allen, G.
    HAEMOPHILIA, 2017, 23 (01) : E39 - E42
  • [10] Long-term efficacy and safety of prophylactic treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe haemophilia A: Final longitudinal analysis of A-LONG/kids A-LONG and ASPIRE
    Konkle, B.
    Young, G.
    Liesner, R.
    Mahlangu, J.
    Brown, S. A.
    Nolan, B.
    Tripkovic, N.
    Feng, J.
    Barnowski, C.
    HAEMOPHILIA, 2019, 25 : 55 - 55
12345